1.Risk Prediction and Management of Chronic Kidney Disease in People Living with Type 2 Diabetes Mellitus
Ying-Guat OOI ; Tharsini SARVANANDAN ; Nicholas Ken Yoong HEE ; Quan-Hziung LIM ; Sharmila S. PARAMASIVAM ; Jeyakantha RATNASINGAM ; Shireene R. VETHAKKAN ; Soo-Kun LIM ; Lee-Ling LIM
Diabetes & Metabolism Journal 2024;48(2):196-207
People with type 2 diabetes mellitus have increased risk of chronic kidney disease and atherosclerotic cardiovascular disease. Improved care delivery and implementation of guideline-directed medical therapy have contributed to the declining incidence of atherosclerotic cardiovascular disease in high-income countries. By contrast, the global incidence of chronic kidney disease and associated mortality is either plateaued or increased, leading to escalating direct and indirect medical costs. Given limited resources, better risk stratification approaches to identify people at risk of rapid progression to end-stage kidney disease can reduce therapeutic inertia, facilitate timely interventions and identify the need for early nephrologist referral. Among people with chronic kidney disease G3a and beyond, the kidney failure risk equations (KFRE) have been externally validated and outperformed other risk prediction models. The KFRE can also guide the timing of preparation for kidney replacement therapy with improved healthcare resources planning and may prevent multiple complications and premature mortality among people with chronic kidney disease with and without type 2 diabetes mellitus. The present review summarizes the evidence of KFRE to date and call for future research to validate and evaluate its impact on cardiovascular and mortality outcomes, as well as healthcare resource utilization in multiethnic populations and different healthcare settings.
2.A summary of the Malaysian Clinical Practice Guidelines on the management of postmenopausal osteoporosis, 2022
Terence Ing WEI ONG ; Lee Ling LIM ; Siew Pheng CHAN ; Winnie Siew SWEE CHEE ; Alan Swee HOCK CH’NG ; Elizabeth GAR MIT CHONG ; Premitha DAMODARAN ; Fen Lee HEW ; Luqman bin IBRAHIM ; Hui Min KHOR ; Pauline Siew MEI LAI ; Joon Kiong LEE ; Ai Lee LIM ; Boon Ping LIM ; Sharmila Sunita PARAMASIVAM ; Jeyakantha RATNASINGAM ; Yew Siong SIOW ; Alexander Tong BOON TAN ; Nagammai THIAGARAJAN ; Swan Sim YEAP
Osteoporosis and Sarcopenia 2023;9(2):60-69
Objectives:
The aim of these Clinical Practice Guidelines is to provide evidence-based recommendations to assist healthcare providers in the screening, diagnosis and management of patients with postmenopausal osteoporosis (OP).
Methods:
A list of key clinical questions on the assessment, diagnosis and treatment of OP was formulated. A literature search using the PubMed, Medline, Cochrane Databases of Systematic Reviews, and OVID electronic databases identified all relevant articles on OP based on the key clinical questions, from 2014 onwards, to update from the 2015 edition. The articles were graded using the SIGN50 format. For each statement, studies with the highest level of evidence were used to frame the recommendation.
Results:
This article summarizes the diagnostic and treatment pathways for postmenopausal OP. Risk stratification of patients with OP encompasses clinical risk factors, bone mineral density measurements and FRAX risk estimates. Non-pharmacological measures including adequate calcium and vitamin D, regular exercise and falls prevention are recommended. Pharmacological measures depend on patients’ fracture risk status. Very high-risk individuals are recommended for treatment with an anabolic agent, if available, followed by an anti-resorptive agent. Alternatively, parenteral anti-resorptive agents can be used. High-risk individuals should be treated with anti-resorptive agents. In low-risk individuals, menopausal hormone replacement or selective estrogen receptor modulators can be used, if indicated. Patients should be assessed regularly to monitor treatment response and treatment adjusted, as appropriate.
Conclusions
The pathways for the management of postmenopausal OP in Malaysia have been updated. Incorporation of fracture risk stratification can guide appropriate treatment.
3.Difficult and failed intubation in Caesarean general anaesthesia: a four-year retrospective review.
Yi Lin LEE ; Michelle Leanne LIM ; Wan Ling LEONG ; Eileen LEW
Singapore medical journal 2022;63(3):152-156
INTRODUCTION:
General anaesthesia is associated with higher maternal morbidity and mortality when compared with regional anaesthesia, related mainly to failure of intubation, hypoxia and aspiration. The aim of this retrospective review was to define the incidence of failed and difficult intubation in parturients undergoing general anaesthesia for Caesarean delivery at a high-volume obstetric hospital in Singapore.
METHODS:
All parturients who underwent Caesarean delivery under general anaesthesia from 2013 to 2016 were identified and their medical records were reviewed to extract pertinent data. Difficult intubation was defined as 'requiring more than one attempt at intubation or documented as such, based on the opinion of the anaesthetist'. A failed intubation was defined as 'inability to intubate the trachea, with subsequent abandonment of intubation as a means of airway management'.
RESULTS:
Records of 660 Caesarean sections under general anaesthesia were extracted. The mean age of the parturients was 32.1 ± 5.5 years and the median body mass index was 27.5 (interquartile range 24.6-31.1) kg/m2. Rapid sequence induction with cricoid pressure was employed for all patients, with thiopentone and succinylcholine being administered for 91.2% and 98.1% of patients, respectively. There were 33 difficult intubations among 660 patients, yielding an incidence of 5.0%. Junior trainees performed about 90% of all intubations and 28 (84.8%) out of 33 difficult intubations. Repeat intubations were performed by senior residents/fellows (57.1%) and consultants (14.3%). No instance of failed intubation was reported.
CONCLUSION
The local incidence of difficult obstetric intubation was one in 20. No failure of intubation was observed.
Adult
;
Airway Management
;
Anesthesia, General
;
Cesarean Section
;
Female
;
Humans
;
Intubation, Intratracheal
;
Pregnancy
;
Retrospective Studies
4.Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting.
Jonathan YAP ; Mun Yee THAM ; Jalene POH ; Dorothy TOH ; Cheng Leng CHAN ; Toon Wei LIM ; Shir Lynn LIM ; Yew Woon CHIA ; Yean Teng LIM ; Jonathan CHOO ; Zee Pin DING ; Ling Li FOO ; Simin KUO ; Yee How LAU ; Annie LEE ; Khung Keong YEO
Annals of the Academy of Medicine, Singapore 2022;51(2):96-100
INTRODUCTION:
Despite reports suggesting an association between COVID-19 mRNA vaccination and pericarditis and myocarditis, detailed nationwide population-based data are sparsely available. We describe the incidence of pericarditis and myocarditis by age categories and sex after COVID-19 mRNA vaccination from a nationwide mass vaccination programme in Singapore.
METHODS:
The incidence of adjudicated cases of pericarditis and myocarditis following COVID-19 mRNA vaccination that were reported to the vaccine safety committee between January to July 2021 was compared with the background incidence of myocarditis in Singapore.
RESULTS:
As of end July 2021, a total of 34 cases were reported (9 pericarditis only, 14 myocarditis only, and 11 concomitant pericarditis and myocarditis) with 7,183,889 doses of COVID-19 mRNA vaccine administered. Of the 9 cases of pericarditis only, all were male except one. The highest incidence of pericarditis was in males aged 12-19 years with an incidence of 1.11 cases per 100,000 doses. Of the 25 cases of myocarditis, 80% (20 cases) were male and the median age was 23 years (range 12-55 years) with 16 cases after the second dose. A higher-than-expected number of cases were seen in males aged 12-19 and 20-29 years, with incidence rates of 3.72 and 0.98 case per 100,000 doses, respectively.
CONCLUSION
Data from the national registry in Singapore indicate an increased incidence of pericarditis and myocarditis in younger men after COVID-19 mRNA vaccination.
Adolescent
;
Adult
;
COVID-19/prevention & control*
;
COVID-19 Vaccines/adverse effects*
;
Child
;
Female
;
Humans
;
Male
;
Middle Aged
;
Myocarditis/etiology*
;
Pericarditis/etiology*
;
RNA, Messenger
;
SARS-CoV-2
;
Vaccination/adverse effects*
;
Vaccines, Synthetic
;
Young Adult
;
mRNA Vaccines
5.Development and feasibility of a mobile-based vestibular rehabilitation therapy application for healthy older adults.
Lee Huan TEE ; Wei Wei SEAH ; Christina Hui Ling CHIA ; Eng Chuan NEOH ; Peter LIM ; Sze Wong LIAW ; Peng Shorn SIEW ; Eu Chin HO
Annals of the Academy of Medicine, Singapore 2022;51(8):514-516
6.National surgical antibiotic prophylaxis guideline in Singapore.
Wei Teng Gladys CHUNG ; Humaira SHAFI ; Jonathan SEAH ; Parthasarathy PURNIMA ; Taweechai PATUN ; Kai Qian KAM ; Valerie Xue Fen SEAH ; Rina Yue Ling ONG ; Li LIN ; Robin Sing Meng CHOO ; Pushpalatha LINGEGOWDA ; Cheryl Li Ling LIM ; Jasmine Shimin CHUNG ; Nathalie Grace S Y CHUA ; Tau Hong LEE ; Min Yi YAP ; Tat Ming NG ; Jyoti SOMANI
Annals of the Academy of Medicine, Singapore 2022;51(11):695-711
INTRODUCTION:
Institutional surgical antibiotic prophylaxis (SAP) guidelines are in place at all public hospitals in Singapore, but variations exist and adherence to guidelines is not tracked consistently. A national point prevalence survey carried out in 2020 showed that about 60% of surgical prophylactic antibiotics were administered for more than 24 hours. This guideline aims to align best practices nationally and provides a framework for audit and surveillance.
METHOD:
This guideline was developed by the National Antimicrobial Stewardship Expert Panel's National Surgical Antibiotic Prophylaxis Guideline Development Workgroup Panel, which comprises infectious diseases physicians, pharmacists, surgeons and anaesthesiologists. The Workgroup adopted the ADAPTE methodology framework with modifications for the development of the guideline. The recommended duration of antibiotic prophylaxis was graded according to the strength of consolidated evidence based on the scoring system of the Singapore Ministry of Health Clinical Practice Guidelines.
RESULTS:
This National SAP Guideline provides evidence-based recommendations for the rational use of antibiotic prophylaxis. These include recommended agents, dose, timing and duration for patients undergoing common surgeries based on surgical disciplines. The Workgroup also provides antibiotic recommendations for special patient population groups (such as patients with β-lactam allergy and patients colonised with methicillin-resistant Staphylococcus aureus), as well as for monitoring and surveillance of SAP.
CONCLUSION
This evidence-based National SAP Guideline for hospitals in Singapore aims to align practices and optimise the use of antibiotics for surgical prophylaxis for the prevention of surgical site infections while reducing adverse events from prolonged durations of SAP.
Humans
;
Antibiotic Prophylaxis
;
Anti-Bacterial Agents/therapeutic use*
;
Methicillin-Resistant Staphylococcus aureus
;
Singapore
;
Surgeons
;
Hospitals, Public
7.Academy of Medicine, Singapore clinical guideline on endoscopic surveillance and management of gastric premalignant lesions.
Vikneswaran NAMASIVAYAM ; Calvin J KOH ; Stephen TSAO ; Jonathan LEE ; Khoon Lin LING ; Christopher KHOR ; Tony LIM ; James Weiquan LI ; Aung Myint OO ; Benjamin C H YIP ; Ikram HUSSAIN ; Tju Siang CHUA ; Bin Chet TOH ; Hock Soo ONG ; Lai Mun WANG ; Jimmy B Y SO ; Ming THE ; Khay Guan YEOH ; Tiing Leong ANG
Annals of the Academy of Medicine, Singapore 2022;51(7):417-435
Gastric cancer (GC) has a good prognosis, if detected at an early stage. The intestinal subtype of GC follows a stepwise progression to carcinoma, which is treatable with early detection and intervention using high-quality endoscopy. Premalignant lesions and gastric epithelial polyps are commonly encountered in clinical practice. Surveillance of patients with premalignant gastric lesions may aid in early diagnosis of GC, and thus improve chances of survival. An expert professional workgroup was formed to summarise the current evidence and provide recommendations on the management of patients with gastric premalignant lesions in Singapore. Twenty-five recommendations were made to address screening and surveillance, strategies for detection and management of gastric premalignant lesions, management of gastric epithelial polyps, and pathological reporting of gastric premalignant lesions.
Adenomatous Polyps
;
Endoscopy
;
Humans
;
Precancerous Conditions/therapy*
;
Singapore
;
Stomach Neoplasms/therapy*
8.Oral Presentation – Clinical and Translational Research
Choon Hoong Chung ; Yee Lynn Soh ; Thinaesh Manoharan ; Arwind Raj ; Dulmini Perera ; Htoo Htoo Kyaw Soe ; Nan Nitra Than ; Lilija Bancevica ; Žanna Kovalova ; Dzintars Ozols ; Ksenija Soldatenkova ; Lim Pyae Ying ; Tay Siow Phing ; Wong Jin Shyan ; Andrew Steven Sinsoon ; Nursabrina Alya Ricky Ramsis ; Nina Azwina Kimri ; Henry Rantai Gudum ; Man Le Ng ; Sze Er Lim ; Hui Yu Kim ; Yee Wan Lee ; Soo Kun Lim ; Sharven Raj ; Mohd Nasir Mohd Desa ; Nurul Syazrah Anuar ; Nurshahira Sulaiman ; Hui Chin Ting ; Zhi Ling Loo ; Choey Yee Lew ; Alfand Marl F Dy Closas ; Tzi Shin Toh ; Jia Wei Hor ; Yi Wen Tay ; Jia Lun Lim ; Lu Yian Tan ; Jie Ping Schee ; Lei Cheng Lit ; Ai Huey Tan ; Shen Yang Lim ; Zhu Shi Wong ; Nur Raziana binti Rozi ; Soo Kun Lim
International e-Journal of Science, Medicine and Education 2022;16(Suppl1):7-14
10.Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
Choon Jin OOI ; Ida HILMI ; Rupa BANERJEE ; Sai Wei CHUAH ; Siew Chien NG ; Shu Chen WEI ; Govind K MAKHARIA ; Pises PISESPONGSA ; Min Hu CHEN ; Zhi Hua RAN ; Byong Duk YE ; Dong Il PARK ; Khoon Lin LING ; David ONG ; Vineet AHUJA ; Khean Lee GOH ; Jose SOLLANO ; Wee Chian LIM ; Wai Keung LEUNG ; Raja Affendi Raja ALI ; Deng Chyang WU ; Evan ONG ; Nazri MUSTAFFA ; Julajak LIMSRIVILAI ; Tadakazu HISAMATSU ; Suk Kyun YANG ; Qin OUYANG ; Richard GEARY ; Janaka H DE SILVA ; Rungsun RERKNIMITR ; Marcellus SIMADIBRATA ; Murdani ABDULLAH ; Rupert WL LEONG ;
Intestinal Research 2019;17(3):285-310
The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn's disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.
Adalimumab
;
Asia
;
Asian Continental Ancestry Group
;
Biological Factors
;
Biosimilar Pharmaceuticals
;
Colitis
;
Colitis, Ulcerative
;
Consensus
;
Cooperative Behavior
;
Crohn Disease
;
Gastroenterology
;
Hepatitis B
;
Humans
;
Immunologic Factors
;
Inflammatory Bowel Diseases
;
Infliximab
;
Pharmacogenetics
;
Philippines
;
Practice Guidelines as Topic
;
Tuberculosis
;
Ulcer


Result Analysis
Print
Save
E-mail